Blood test may predict immunotherapy success in cancer patients

NCT ID NCT07376512

Not yet recruiting Knowledge-focused Sponsor: Centre Georges Francois Leclerc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatment. The goal is to find biomarkers that show who is likely to respond well, helping personalize cancer care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN CANCER) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHU Besançon - Service Dermatologie

Besançon, 25000, France
CHU Besançon - Service Pneumologie Oncologie Thoracique

Besançon, 25000, France
CHU Dijon - Service Oncologie Médicale

Dijon, 21000, France
Centre Georges-François Leclerc

Dijon, 21000, France
Centre Leon Berard - Service Oncologie Médicale

Lyon, 69000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.